Roche plan to voluntarily withdraw the marketing authorisation for daclizumab (Zenapax™) concentrate for solution for infusion (25mg/5ml) in all countries where it is licensed.  This is a commercial decision due to the availability of alternative treatments, and hence diminished market demands. 

Daclizumab is currently licensed in the UK for the prophylaxis of acute organ rejection (see link to SPC below for details).  The licence will be withdrawn in Europe from 31 December 2008; however, stocks of the product existing in pharmacies and hospitals should continue to be available to patients until the end of shelf life expiry in 2010.